Sotrovimab versus usual care in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY P. et al, (2025), The Lancet Infectious Diseases
Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19: a randomised, controlled, open-label, platform trial (RECOVERY)
HORBY PW. et al, (2025), The Lancet Infectious Diseases
Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression
Greene T. et al, (2025), Clinical Journal of the American Society of Nephrology, 20, 632 - 641
Empagliflozin lowers serum uric acid in chronic kidney disease: exploratory analyses from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2025), Nephrol Dial Transplant, 40, 720 - 730
Correction: Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.
Buccheri S. et al, (2025), Trials, 26
Large simple randomized controlled trials-from drugs to medical devices: lessons from recent experience.
Buccheri S. et al, (2025), Trials, 26
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.
Judge PK. et al, (2024), Nephrol Dial Transplant
Accelerating Evidence Generation: Addressing Critical Challenges and Charting a Path Forward
LANDRAY M., (2024), Journal of Clinical and Translational Science
Overcoming the barriers to better evidence generation from clinical trials
LANDRAY M., (2024), Trials
In Practice: RECOVERY Trial
HORBY P. et al, (2024), Principles and Practice of Emergency Research Response
Relative Effectiveness of High-Dose vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults with Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical Trial.
Christensen J. et al, (2024), Circ Cardiovasc Qual Outcomes
High-Dose vs Standard-Dose Influenza Vaccine in Chronic Kidney Disease: A Secondary Analysis of DANFLU-1.
Bartholdy KV. et al, (2024), J Am Coll Cardiol
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) for hospitalised patients with COVID-19: prospective meta-analysis of randomised trials
LANDRAY M. et al, (2024), The Lancet Diabetes and Endocrinology
Frailty, multimorbidity and polypharmacy: exploratory analyses of the effects of empagliflozin from the EMPA-KIDNEY trial.
Mayne KJ. et al, (2024), Clin J Am Soc Nephrol, 19, 1119 - 1129
The Integration of Clinical Trials With the Practice of Medicine: Repairing a House Divided.
Angus DC. et al, (2024), JAMA